# Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis

> **NCT07181811** · NA · NOT_YET_RECRUITING · sponsor: **Anza Memon** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **OTHER:** Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments

## Key facts

- **NCT ID:** NCT07181811
- **Lead sponsor:** Anza Memon
- **Sponsor class:** FED
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2028-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07181811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07181811, "Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07181811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*